The purpose of this study was to investigate the potential therapeutic qualities of 9-tetrahydrocannabinol (THC)
with respect to slowing or halting the hallmark characteristics of Alzheimer’s disease. N2a-variant amyloid- protein precursor
(APP) cells were incubated with THC and assayed for amyloid- (A) levels at the 6-, 24-, and 48-hour time marks. THC was
also tested for synergy with caffeine, in respect to the reduction of the A level in N2a/APPswe cells. THC was also tested
to determine if multiple treatments were beneficial. The MTT assay was performed to test the toxicity of THC. Thioflavin T
assays and western blots were performed to test the direct anti-A aggregation significance of THC. Lastly, THC was tested
to determine its effects on glycogen synthase kinase-3 (GSK-3) and related signaling pathways. From the results, we have
discovered THC to be effective at loweringA levels in N2a/APPswe cells at extremely lowconcentrations in a dose-dependent
manner. However, no additive effect was found by combining caffeine and THC together. We did discover that THC directly
interacts with A peptide, thereby inhibiting aggregation.
Furthermore, THC was effective at lowering both total GSK-3 levels and phosphorylated GSK-3 in a dose-dependent manner at low concentrations. At the treatment concentrations, no toxicity was observed and the CB1 receptor was not significantly upregulated. Additionally, low doses of THC can enhance mitochondria function and does not inhibit melatonin’s enhancement of mitochondria function. These sets of data strongly suggest that THC could be a potential therapeutic treatment option for Alzheimer’s disease through multiple functions and pathways.